Navigation Links
Amira Pharmaceuticals, Inc. Expands its Scientific Advisory Board and Appoints Dr. Paul Anderson, Professor Jerold Chun and Professor Andrew Tager
Date:1/8/2009

SAN DIEGO, Jan. 8 /PRNewswire/ -- Amira Pharmaceuticals, a small molecule pharmaceutical company focused on the discovery and early development of compounds to treat inflammatory diseases, today announced the appointment of Dr. Paul Anderson, Professor Jerold Chun and Professor Andrew Tager to its Scientific Advisory Board. This further strengthens the Board that includes Professor Frank Austen (Professor of Respiratory and Inflammatory diseases, Harvard Medical School), Professor Sally Wenzel (Professor of Medicine, University of Pittsburgh), and Professor Joseph Witztum (Professor of Medicine, University of California, San Diego).

Dr. Paul Anderson has more than 40 years of pharmaceutical research and managerial experience. He spent 30 years at Merck Research Laboratories. He retired from Merck in 1994 and joined DuPont-Merck Pharmaceuticals as Senior Vice President for Chemical and Physical Sciences and later, in 2001, he joined Bristol-Myers Squibb as Vice President for Drug Discovery and Site Head. He retired from BMS in 2002. Dr. Anderson is a past president of the American Chemical Society. Dr. Anderson's contributions to science have been recognized by numerous awards, including the National Academy of Sciences Award for Chemistry in Service to Society, the Perkin Medal from the Society of Chemical Industry and the American Chemical Society's highest honor, the Priestly Medal.

Dr. Jerold Chun is a Professor at The Scripps Research Institute in La Jolla, CA. He is a recognized leader in the field of receptor-mediated Lysophospholipid signaling. Dr. Chun's group studies the development and function of the mammalian nervous system in particular in relation to bioactive lipid signaling. Dr. Chun's group cloned and functionally identified the first lysophospholipid receptor. He has published over 160 manuscripts, and received multiple awards and fellowships including the Medic
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
2. Amira Pharmaceuticals Appoints First Vice President of Development
3. Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
4. Dr. Dennis Fenton and Dr. Steve Kaldor Join Amira Board of Directors
5. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
6. Amira Announces the Successful Completion of GLP Toxicity Studies for a Novel DP2 Antagonist.
7. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... New York, NY (PRWEB) May 20, 2013 ... to protecting the rights of victims injured by defective ... South Dakota man who alleges that use of the ... The suit was filed on April 30, 2013, ... of Louisiana (Case No. 6:13-cv-0888), where it is one ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 Mirena ... in the multidistrict litigation recently established in U.S. District ... reports. According to court records, the litigation’s first ... time appointments to Plaintiff’s leadership positions were discussed. ... in the Southern District of New York, all of ...
(Date:5/20/2013)... Salt Lake Community College’s Know Greater Heroes program ... winners for 2013. As part of the award, the ... is a leadership training program that involves SLCC athletes who ... eat right, be active, and avoid drugs and alcohol. , ... program each year, and visit more than 30 schools each ...
(Date:5/20/2013)... The judge overseeing pretrial proceedings in ... specifically for female lawyers to be included in a ... Group LLP acknowledges the judge’s request, noting that its ... providing information on Mirena side effects and how to ... the addition of some female lawyers to the committee. ...
(Date:5/20/2013)... 2013 While Huntington,s disease (HD) is currently ... disease-modifying therapies in development may slow or minimize ... depends upon the identification of reliable and sensitive ... these biomarkers may eventually be used as outcome ... helpful to monitor changes during the time prior ...
Breaking Medicine News(10 mins):Health News:Taking Actos for Two Years Caused Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP on Behalf of South Dakota Man 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 3Health News:SLCC Know Greater Heroes Program Named to Select 25 2Health News:SLCC Know Greater Heroes Program Named to Select 25 3Health News:Mirena IUD Lawsuit Update: Judge Calls for More Input from Female Lawyers, Notes Rottenstein Law Group LLP 2Health News:Leading researchers report on the elusive search for biomarkers in Huntington's disease 2Health News:Leading researchers report on the elusive search for biomarkers in Huntington's disease 3
... Cleaners Proven to Protect and Even Improve Health, ... homes is,increasingly contaminated and polluted, and now studies have ... not only allergy and asthma,symptoms but also a variety ... clots., Studies are emerging that prove poor indoor ...
... the type diagnosed in Sen. Edward Kennedy , , MONDAY, ... is showing promise against the same general type of ... reporting. , The vaccine, when given with chemotherapy, more ... tumors. Kennedy was diagnosed last month with a malignant ...
... The discovery of new genetic mutations involved in inflammatory ... these common conditions, two scientists told the annual conference ... 2 June). , Dr.Alexandra ... Netherlands, and Dr. Eleonora Festen, from the University of ...
... ST. PETERSBURG, Fla., June 2 The Advanced,Wound Management ... announced,today that its negative pressure wound therapy (NPWT) products ... areas included in the,first phase of the competitive bidding ... (CMS) in the U.S. The program, which is,scheduled to ...
... family of CCRCs with expansion into Alabama;,Community to ... June 2 ACTS Retirement-Life,Communities, a premier not-for-profit ... its acquisition of Carlton Cove, a,continuing care retirement ... renamed Magnolia Trace and become the 19th ACTS,continuing ...
... the body,s own tissues and organs, wreaking havoc and ... of these diseases are so obscure, no effective treatment ... Weizmann Institute scientists have developed a method that in ... diseases effectively without necessarily knowing their exact cause. Their ...
Cached Medicine News:Health News:Studies Find Poor Indoor Air Quality Can Lead to Major Health Problems 2Health News:Studies Find Poor Indoor Air Quality Can Lead to Major Health Problems 3Health News:Vaccine May Boost Survival of Brain Cancer Patients 2Health News:Vaccine May Boost Survival of Brain Cancer Patients 3Health News:Discovery of new family of genetic mutations involved in inflammatory intestinal disease 2Health News:Discovery of new family of genetic mutations involved in inflammatory intestinal disease 3Health News:Smith & Nephew Negative Pressure Wound Therapy Products To Be Available To Patients Through the Medicare Part B Competitive Bidding Process 2Health News:Smith & Nephew Negative Pressure Wound Therapy Products To Be Available To Patients Through the Medicare Part B Competitive Bidding Process 3Health News:Smith & Nephew Negative Pressure Wound Therapy Products To Be Available To Patients Through the Medicare Part B Competitive Bidding Process 4Health News:Smith & Nephew Negative Pressure Wound Therapy Products To Be Available To Patients Through the Medicare Part B Competitive Bidding Process 5Health News:ACTS Retirement-Life Communities Completes Carlton Cove Acquisition 2Health News:Weizmann Institute scientists develop a new approach to treating autoimmune disease 2
(Date:5/20/2013)... , BERLIN and ... Arthroscopy Devices Market to 2018 ... Invasive Procedures to Drive Future Growth" looks at the ... six arthroscopy device market segments: arthroscopes, arthroscopy shavers, arthroscopy ... systems, and arthroscopy visualization systems. The report provides comprehensive ...
(Date:5/20/2013)... 2013  Rhythm announced today the presentation of results ... of gastroparesis symptoms among diabetic patients in the U.S. ... among patients with both type 1 and type 2 ... with the more common type 2 disease. ... Associate Professor of Medicine at Harvard Medical School and ...
(Date:5/20/2013)... May 20, 2013  AbbVie (NYSE: ... Phase 3 clinical study called SONAR (Study Of ... of the investigational compound atrasentan - when added to ... in patients with stage 2 to 4 chronic ... is a large, multinational, double-blind, placebo-controlled clinical study ...
Breaking Medicine Technology:Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 2Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 3Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 4Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 2Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 3Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6
... Inc. (Nasdaq: MAPP ) today announced that the ... Stifel Nicolaus Healthcare Conference Thursday, September 8, at ... Sciences Conference Wednesday, September 21, at 9:30 a.m. ET in ... will be available on the Investor Relations section of MAP ...
... THOUSAND OAKS, Calif., Sept. 6, 2011 Amgen (NASDAQ: ... on Thursday, Sept. 8, 2011, at The New York Palace ... Time. Arvind Sood, vice president of Investor Relations at Amgen, ... from the Events Calendar on Amgen,s website, www.amgen.com , ...
Cached Medicine Technology:
... Use , The new Finnpipette Novus is so user-friendly ... a few minutes. With the intuitive instantly familiar menu ... pipetting functions you need quickly and easily. The large, ... full names of all functions. The easily accessible ...
... of a 384 Well Plate at Once , ... plates, you need a pipettor that can adapt ... you get with our 16-channel Impact pipettor., Available ... innovation was specifically designed to allow you to ...
... of a 384 Well Plate at Once , ... plates, you need a pipettor that can adapt ... you get with our 16-channel Impact pipettor., Available ... innovation was specifically designed to allow you to ...
... The Seal-Away CS and Alliance ... designed for the introduction of ... coronary sinus from a superior ... Jude Medical's outstanding peel-away introducer ...
Medicine Products: